Study finds that metformin plus myoinositol significantly increases conception rates in women with polycystic ovarian syndrome, indicating potential for improved fertility.
One of the most prevalent endocrine illnesses that affect women during their reproductive years is polycystic ovarian syndrome (PCOS). Hyperandrogenism, protracted anovulation, and irregular menstrual cycles are its hallmarks. About 50% of PCOS individuals are reported to have impaired insulin receptor phosphorylation. The development of insulin resistance (IR), which may reduce female fertility by disrupting ovulation, is one of the most significant PCOS pathological features. Numerous studies have demonstrated that metformin and myoinositol are the most effective first-line treatments for restoring normal menstrual periods in PCOS-affected individuals. Several studies revealed that patients receiving both metformin and myoinositol experienced a statistically significant increase in conception rates after 24 weeks of treatment.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: